XML 57 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Operations - Additional Information (Detail)
Surgery in Millions
 12 Months Ended
Feb. 25, 2020
USD ($)
Dec. 31, 2019
USD ($)
Product
_People
Case
Patient
Dec. 31, 2018
USD ($)
Surgery
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Operations [Line Items]          
Number of products approved | Product   2      
Number of patients | Patient   60      
Accumulated deficit   $ 465,286,000 $ 408,493,000    
Working capital   30,200,000      
Cash and cash equivalents   22,214,000 $ 45,261,000    
Proceeds from issuance of common stock   $ 22,627,000   $ 41,515,000 $ 8,404,000
Subsequent Event [Member]          
Operations [Line Items]          
Proceeds from issuance of common stock $ 20,300,000        
Adjustments to additional paid in capital, stock issued, issuance costs $ 300,000        
YUTIQ [Member]          
Operations [Line Items]          
Number of new cases of blindness every year | Case   30,000      
YUTIQ [Member] | Minimum [Member]          
Operations [Line Items]          
Number of people affected by posterior segment of eye in U.S. each year | _People   60,000      
YUTIQ [Member] | Maximum [Member]          
Operations [Line Items]          
Number of people affected by posterior segment of eye in U.S. each year | _People   100,000      
DEXYCU [Member]          
Operations [Line Items]          
Number of cataract surgeries performed in U.S. | Surgery     3.8    
Estimated annual growth rate of cataract surgeries performed in U.S.   8.00%